Chelsea Therapeutics

Lundbeck completes acquisition of Chelsea Therapeutics

Wednesday, June 25, 2014 02:06 PM

Lundbeck has completed its acquisition of Chelsea Therapeutics International for $6.44 per share in cash and non-transferable contingent value rights that may pay up to an additional $1.50 per share upon achievement of certain sales milestones.

More... »

WIRB Copernicus Group

Lundbeck to acquire Chelsea Therapeutics

Friday, May 9, 2014 12:25 PM

H. Lundbeck of Denmark and North Carolina-based Chelsea Therapeutics International have entered into a definitive agreement under which Lundbeck will acquire Chelsea.

More... »

CRF Health eCOA webinar series

FDA approves Northera to treat neurogenic orthostatic hypotension

Wednesday, February 19, 2014 03:53 PM

The FDA has approved Northera capsules (droxidopa) for the treatment of neurogenic orthostatic hypotension (NOH). NOH is a rare, chronic and often debilitating drop in blood pressure upon standing that is associated with Parkinson's disease, multiple-system atrophy and pure autonomic failure.  

More... »

Chelsea Therapeutics implements $6M cost savings to expand Northera study

Monday, June 11, 2012 12:18 PM

Chelsea Therapeutics International, biopharmaceutical development company, reports that all corporate officers and members of its board of directors volunteered to receive a 25% reduction in compensation until data from its ongoing phase III study of Northera (droxidopa) is available.

More... »

Chelsea Therapeutics' phase II Droxidopa trial meets primary endpoint

Friday, December 23, 2011 11:01 AM

Chelsea Therapeutics International has reported results of a phase II dose-finding study designed to evaluate the safety and determine the potential therapeutic dose range of droxidopa, alone or in combination with carbidopa, that might be effective for the treatment of fibromyalgia.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs